Overview

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
- To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. - To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients
Phase:
Phase 4
Details
Lead Sponsor:
Thomas Jefferson University
Collaborator:
GlaxoSmithKline
Treatments:
Bupropion